Biotech News
Related news
RVMDRevolution Medicines2026-10-05 12:00 EST
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
TEVATeva Pharmaceutical Industries2026-10-02 12:00 EST
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
TEVATeva Pharmaceutical Industries2026-09-18 20:32 EST
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
LEGNLegend Biotech Corporation2026-09-10 12:00 EST
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
FATEFate Therapeutics2026-09-09 11:00 EST
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
RVMDRevolution Medicines2026-09-02 21:50 EST
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
FATEFate Therapeutics2026-08-14 11:00 EST
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
REGNRegeneron Pharmaceuticals2026-10-01 15:35 EST
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
ELVNEnliven Therapeutics2026-08-31 22:05 EST
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
BMYBMYBristol-Myers Squibb Company2026-08-13 21:12 EST
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
Vaccinex
Vaccinex is a biotechnology company focused on antibody therapies and immunology, with a history of pursuing difficult oncology and neurodegenerative targets. Its story is tied to platform science and the challenge of turning it into durable value.
Recent company news
VCNXVaccinex2026-04-30 00:05 EST
Vaccinex Reports 2025 Annual Financial Results
VCNXVaccinex2025-12-23 13:01 EST
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
VCNXVaccinex2025-05-27 12:45 EST
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
VCNXVaccinex2025-04-21 12:45 EST
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
VCNXVaccinex2025-03-07 22:15 EST
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
Stock data
- Close
- 1.03 USD
- Market cap
- —
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States